Lowers the risk of stroke and systemic embolism. ANDA 208048, held by Dr Reddys. Dabigatran Etexilate Mesylate.
As of Nov 16, 2026, ANDA 208048 (Dabigatran Etexilate Mesylate), held by Dr Reddys, was first approved by FDA on Jan 28, 2025, with 0 approved supplements and 0 published complete response letters.
Dabigatran etexilate capsules is a direct thrombin inhibitor indicated:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 28, 2025 | Original application | Approved |
| Dabigatran Etexilate MesylateEQ 75MG BASE · capsule;oral | Dabigatran Etexilate Mesylate | Rx |
| Dabigatran Etexilate MesylateEQ 110MG BASE · capsule;oral | Dabigatran Etexilate Mesylate | Rx |
| Dabigatran Etexilate MesylateEQ 150MG BASE · capsule;oral | Dabigatran Etexilate Mesylate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters